Biocon gets approval for anti-CD-6 psoriasis biologic
This article was originally published in Scrip
As Biocon receives marketing authorization in India for its anti-CD6 monoclonal antibody, itolizumab, for chronic plaque psoriasis, analysts suggest that large markets like the US, EU and Japan hold significant promise for the product.
You may also be interested in...
Novartis thwarts Sun’s efforts to commercialize nilotinib in India, though the Indian firm indicates that its actions are covered under a local Bolar-type provision and that it has no plans to market the anticancer while the originator's patent stands valid.
Tildrakizumab debuts in Japan, marking a key milestone for Sun Pharma, though heavyweight competitors including same class rival Skyrizi are already available on the market there.
Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.